Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A prospective, single center, single arm, phase II clinical trial of Pyrotinib combined with
pemetrexed plus carboplatin in the first-line treatment of patients with HER2 mutant or
amplified recurrent / metastatic non-small cell lung cancer